Company
Alphyn Biologics
is developing breakthrough therapies to treat the world’s most challenging, severe, and common skin diseases.
Also known as Alphyn Biologics, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Annapolis, Maryland, United States
- Founded
- 2019
- Legal name
- Alphyn Biologics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Alphyn is a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics® (MTT™) for severe and prevalent skin diseases based on our Zabalafin Platform (AB-101 Platform).
Funding snapshot
- Total raised
- $9.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $5.2M2024-03-28
Funding rounds
- Round, 2024
- $5.2M2024-03-28, SEC form D sold, 18 investors
- Round, 2023
- $1.2M2023-05-19, SEC form D sold, 17 investors
- Round, 2022
- $2.2M2022-05-19, SEC form D sold, 7 investors
- Round, 2020
- $800K2020-01-27, SEC form D sold, 5 investors
Products
- Other
- Zabalafin hydrogel (AB-101a)
Loading relationship preview